Cargando…

In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase

Imatinib is a tailored drug for the treatment of chronic myeloid leukemia (CML), and has substantial activity and a favorable safety profile when used as a single agent in patients with CML in myeloid blast crisis. The megakaryocytic blast crisis in CML occurs rarely and carries a poor prognosis. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: MENG, FANKAI, ZENG, WEN, HUANG, LIFANG, QIN, SHUANG, MIAO, NINGNING, SUN, HANYING, LI, CHUNRUI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919897/
https://www.ncbi.nlm.nih.gov/pubmed/24527087
http://dx.doi.org/10.3892/ol.2014.1780
_version_ 1782303104974192640
author MENG, FANKAI
ZENG, WEN
HUANG, LIFANG
QIN, SHUANG
MIAO, NINGNING
SUN, HANYING
LI, CHUNRUI
author_facet MENG, FANKAI
ZENG, WEN
HUANG, LIFANG
QIN, SHUANG
MIAO, NINGNING
SUN, HANYING
LI, CHUNRUI
author_sort MENG, FANKAI
collection PubMed
description Imatinib is a tailored drug for the treatment of chronic myeloid leukemia (CML), and has substantial activity and a favorable safety profile when used as a single agent in patients with CML in myeloid blast crisis. The megakaryocytic blast crisis in CML occurs rarely and carries a poor prognosis. The aim of the present study was to investigate the effects of imatinib on cluster of differentiation (CD)34(+) cells from patients with CML in the megakaryocytic crisis phase. Bone marrow mononuclear cells (BMNCs) were isolated from patients with CML in the megakaryocytic crisis phase. CD34(+) cells were selected from BMNCs by positive immunomagnetic column separation. Imatinib significantly induced G(1) arrest, reduced the phosphorylation of cyclin-dependent kinase 1 and retinoblastoma proteins and inhibited the proliferation of CD34(+) cells from patients with CML in the megakaryocytic crisis phase. Annexin V/propidium iodide and caspase-3 activity showed that imatinib induced apoptosis. Western blot analysis and protein tyrosine kinase activity assays showed that imatinib inhibited BCR-ABL protein tyrosine kinase activity. The in vitro data thus markedly indicate a potential clinical application of imatinib for patients with CML in the megakaryocytic crisis phase.
format Online
Article
Text
id pubmed-3919897
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-39198972014-02-13 In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase MENG, FANKAI ZENG, WEN HUANG, LIFANG QIN, SHUANG MIAO, NINGNING SUN, HANYING LI, CHUNRUI Oncol Lett Articles Imatinib is a tailored drug for the treatment of chronic myeloid leukemia (CML), and has substantial activity and a favorable safety profile when used as a single agent in patients with CML in myeloid blast crisis. The megakaryocytic blast crisis in CML occurs rarely and carries a poor prognosis. The aim of the present study was to investigate the effects of imatinib on cluster of differentiation (CD)34(+) cells from patients with CML in the megakaryocytic crisis phase. Bone marrow mononuclear cells (BMNCs) were isolated from patients with CML in the megakaryocytic crisis phase. CD34(+) cells were selected from BMNCs by positive immunomagnetic column separation. Imatinib significantly induced G(1) arrest, reduced the phosphorylation of cyclin-dependent kinase 1 and retinoblastoma proteins and inhibited the proliferation of CD34(+) cells from patients with CML in the megakaryocytic crisis phase. Annexin V/propidium iodide and caspase-3 activity showed that imatinib induced apoptosis. Western blot analysis and protein tyrosine kinase activity assays showed that imatinib inhibited BCR-ABL protein tyrosine kinase activity. The in vitro data thus markedly indicate a potential clinical application of imatinib for patients with CML in the megakaryocytic crisis phase. D.A. Spandidos 2014-03 2014-01-02 /pmc/articles/PMC3919897/ /pubmed/24527087 http://dx.doi.org/10.3892/ol.2014.1780 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
MENG, FANKAI
ZENG, WEN
HUANG, LIFANG
QIN, SHUANG
MIAO, NINGNING
SUN, HANYING
LI, CHUNRUI
In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
title In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
title_full In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
title_fullStr In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
title_full_unstemmed In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
title_short In vitro effects of imatinib on CD34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
title_sort in vitro effects of imatinib on cd34(+) cells of patients with chronic myeloid leukemia in the megakaryocytic crisis phase
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919897/
https://www.ncbi.nlm.nih.gov/pubmed/24527087
http://dx.doi.org/10.3892/ol.2014.1780
work_keys_str_mv AT mengfankai invitroeffectsofimatiniboncd34cellsofpatientswithchronicmyeloidleukemiainthemegakaryocyticcrisisphase
AT zengwen invitroeffectsofimatiniboncd34cellsofpatientswithchronicmyeloidleukemiainthemegakaryocyticcrisisphase
AT huanglifang invitroeffectsofimatiniboncd34cellsofpatientswithchronicmyeloidleukemiainthemegakaryocyticcrisisphase
AT qinshuang invitroeffectsofimatiniboncd34cellsofpatientswithchronicmyeloidleukemiainthemegakaryocyticcrisisphase
AT miaoningning invitroeffectsofimatiniboncd34cellsofpatientswithchronicmyeloidleukemiainthemegakaryocyticcrisisphase
AT sunhanying invitroeffectsofimatiniboncd34cellsofpatientswithchronicmyeloidleukemiainthemegakaryocyticcrisisphase
AT lichunrui invitroeffectsofimatiniboncd34cellsofpatientswithchronicmyeloidleukemiainthemegakaryocyticcrisisphase